earnings

Novartis buys Endocyte for $2.1B in latest deal under CEO Narasimhan
Novartis buys Endocyte for $2.1B in latest deal under CEO Narasimhan
Biopharma Dive
Novartis
earnings
M&A
Endocyte
Flag link:
2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
Motley Fool
JNJ
earnings
Pfizer
Merck
Flag link:
Abbott Laboratories Posts Solid Q3 Earnings, Trims Full-Year Forecast
Abbott Laboratories Posts Solid Q3 Earnings, Trims Full-Year Forecast
TheStreet.com
Abbott Labs
earnings
devices
Flag link:
Roche torches a mountain of biobucks, sweeping out a roster of R&D programs in the latest pipeline cleanup
Roche torches a mountain of biobucks, sweeping out a roster of R&D programs in the latest pipeline cleanup
Endpoints
Roche
earnings
R&D
RG6125
Actemra
RG7155
Flag link:
Prescription drugs, lower taxes, power J&J 3Q beat
Prescription drugs, lower taxes, power J&J 3Q beat
Yahoo/AP
JNJ
earnings
Flag link:
J&J posts softer Q3 device sales
J&J posts softer Q3 device sales
MedTech Dive
JNJ
earnings
devices
Flag link:
7 drugmakers to watch during Q3 earnings
7 drugmakers to watch during Q3 earnings
Biopharma Dive
earnings
Novartis
Gilead Sciences
Amgen
Pfizer
GSK
AbbVie
Regeneron
Flag link:
AstraZeneca plc (AZN) Expected to Post Earnings of $0.44 Per Share
AstraZeneca plc (AZN) Expected to Post Earnings of $0.44 Per Share
Daily Political
AstraZeneca
earnings
Flag link:
Medtronic’s Q1 tops The Street
Medtronic’s Q1 tops The Street
Mass Device
Medtronic
devices
earnings
Flag link:
Novo Nordisk's Pricing Pressures Aren't Going Away
Novo Nordisk's Pricing Pressures Aren't Going Away
Motley Fool
Novo Nordisk
earnings
drug pricing
Flag link:
Endologix shares plunge on Q2 earnings miss
Endologix shares plunge on Q2 earnings miss
Mass Device
Endologix
earnings
Flag link:
Endo shares soar on Street-beating Q2
Endo shares soar on Street-beating Q2
Drug Delivery Business News
Endo Pharmaceuticals
earnings
Flag link:
Becton, Dickinson Sees Synergies From Bard With More to Come
Becton, Dickinson Sees Synergies From Bard With More to Come
Motley Fool
devices
earnings
Becton Dickinson
CR Bard
Flag link:
Mylan lowers outlook after Q2 earnings, sales miss estimates
Mylan lowers outlook after Q2 earnings, sales miss estimates
Drug Delivery Business News
Mylan Labs
earnings
Flag link:
Novo Nordisk sees lower US prices next year; second-quarter profit in line with forecasts
Novo Nordisk sees lower US prices next year; second-quarter profit in line with forecasts
CNBC
Novo Nordisk
earnings
drug prices
Flag link:
BioMarin Pharmaceutical Sets Its Sights on $2 Billion
BioMarin Pharmaceutical Sets Its Sights on $2 Billion
Motley Fool
Biomarin
earnings
Flag link:
AnaptysBio Inc.'s Lead Candidate Gets New Priorities -- The Motley Fool
AnaptysBio Inc.'s Lead Candidate Gets New Priorities -- The Motley Fool
Motley Fool
AnaptysBio
earnings
peanut allergy
Flag link:
Intercept superstar: revenues exceeding estimates, solid plans and shares rise 10%
Intercept superstar: revenues exceeding estimates, solid plans and shares rise 10%
GoinPharma
Intercept Pharma
earnings
Flag link:
Oncolytics Biotech (ONCY) Posts Earnings Results, Misses Expectations By $0.25 EPS
Oncolytics Biotech (ONCY) Posts Earnings Results, Misses Expectations By $0.25 EPS
The Daily Political
earnings
Oncolytics
Flag link:
Can MannKind Corporation Avert Bankruptcy?
Can MannKind Corporation Avert Bankruptcy?
Motley Fool
MannKind
earnings
Afrezza
Flag link:

Pages